Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Landos Biopharma Inc
(NQ:
LABP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Landos Biopharma Inc
< Previous
1
2
3
Next >
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
May 11, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024
May 09, 2024
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
April 26, 2024
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
April 01, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Recap: Landos Biopharma Q4 Earnings
March 21, 2024
Via
Benzinga
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
March 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Nasdaq Turns Higher; Akanda Shares Plunge
March 25, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
March 25, 2024
Via
Benzinga
Is the Stock Market Closed on Good Friday 2024?
March 25, 2024
Investors are wondering if the stock market is closed on Good Friday 2024 as they prepare for the upcoming Easter weekend.
Via
InvestorPlace
Landos Biopharma: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Recap: Landos Biopharma Q1 Earnings
May 12, 2023
Via
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
March 25, 2024
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million.
Via
InvestorPlace
Crude Oil Moves Higher; US New Home Sales Fall In February
March 25, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders
March 25, 2024
From
Halper Sadeh LLC
Via
Business Wire
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
March 25, 2024
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
US Stocks Down; Chicago Fed National Activity Index Rises In February
March 25, 2024
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 25, 2024
Via
Benzinga
LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023
March 21, 2024
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Landos Biopharma - Investor Like It Better Than Analysts
March 07, 2024
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease.
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 12, 2023
Via
Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
March 11, 2023
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 09, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 09, 2023
It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 08, 2023
Via
Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
February 28, 2023
From
Landos Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.